They have signed long term agreements with DaVita and Fresenuis which in effect cuts Affy out of the game. Come to find out these Centers had decided to "Pause" the use of Omontys prior to the recall, and to not expand the use in the future, which meant no income for Affy.
I am the only one here who read the part of the new ability to market to Japan and Europe which is a larger market than the US and with less restrictions? Takeda wants to clean up things with the FDA but also want this drug to have international distribution.
enhance your calm bill. That is an old filing and also keep in mind that AMGEN was recently sued for such practices and settled for 24.9 million dollars with the SEC to bury those allegations. So Fresenuis and DaVita have contracts, there are dozens of other companies who also run dialysis center. Stop freaking out as you approach the end of the race.
raj, I have moved from Nirvana to calm and am fine. Lol There are more things to consider:
1) If and when we are able to reintroduce OMONTYS, which is highly uncertain, it will be even more challenging for us to compete in view of the recall and related safety concerns particularly due to the long-term experience with currently marketed products and negative perceptions of OMONTYS' safety. These factors present further challenges to compete and enter into long-term supply agreements with the major operators of dialysis clinics in the U.S. In particular, we may not be able to reach a long-term agreement with either of the largest operators of dialysis clinics in the U.S., DaVita Inc., or DaVita, and Fresenius, because both entered into a long-term supply agreement with Amgen that began in January 2012. In July 2012, Fresenius entered into a short-term supply agreement with Takeda Pharmaceuticals America, Inc., or TPA. In February 2013, Fresenius communicated that it decided to pause further expansion of its OMONTYS pilot program.
2) The specific terms of the Amgen-Fresenius agreement and the Amgen-DaVita agreement have not been publicly disclosed, and we cannot predict how these agreements may impact the commercial opportunity for OMONTYS should it be reintroduced. But these agreements may limit the market opportunity for the product and adversely impact our ability to generate product sales.
you fail to take into consideration long term specialty nursing homes, dozens of other dialysis corporations, and hospitals. The only safety concern that has been made public are the allergic reactions which patients can be tested for, regardless if you have moved on from the investment, i wish you good luck. It is still a high risk investment and i can leave the money in this investment alone until something happens or write it off as a tax loss.
These are all very old news and everyone knew the competitive market place AMGN was putting AFFY into.
Still it is expensive for Dialysis centers to provide AMGN's drug and also for AMGN it is very expensive to manufacture the drug.
One possibility I considered from day one, Takeda might take the money from AMGN and sell it to them 100%.
AMGN has got the know how, marketing capability to make a killing here.